Core Viewpoint - The strategic cooperation agreement between Huajian Medical and Chuangsheng Group aims to explore the tokenization of innovative drug pipeline assets valued at over $1.5 billion, focusing on six major oncology drug pipelines [1][2]. Group 1: Strategic Cooperation Details - Huajian Medical and Chuangsheng Group signed a strategic cooperation agreement to jointly explore the tokenization of innovative drug pipeline assets [1]. - The collaboration involves six innovative oncology drug pipelines, including TST003, TST005, TST786, and three preclinical antibody-drug conjugates TST105, TST106, and TST013 [1]. - These pipelines utilize advanced technologies such as bispecific antibodies, trispecific antibodies, ADCs, and fusion proteins, showcasing global innovation or best-in-class potential [1]. Group 2: Technological and Financial Aspects - Huajian Medical will provide a comprehensive technological solution covering digital initiation, trusted on-chain processes, compliant issuance, and liquidity integration for the pipeline assets [1]. - The cooperation is expected to lock in the R&D value of high-value pipelines, provide new channels for global capital allocation, and accelerate therapy accessibility [2].
华检医疗：与创胜集团探索区块链融资 合作管线估值超15亿美元